More Attention to CVD Risk Assessment in T1DM Urged. ADA and AHA. Diab Care Oct.

Arkiv alla nyheter

More Attention to CVD Risk Assessment in T1DM Urged. ADA and AHA. Diab Care Oct.

Currently no risk prediction model for use in patients with type 1 diabetes mellitus

Despite the known higher risk of cardiovascular disease (CVD) in individuals with type 1 diabetes mellitus (T1DM), the pathophysiology underlying the relationship between cardiovascular events, CVD risk factors, and T1DM is not well understood. Management approaches to CVD reduction have been extrapolated in large part from experience in type 2 diabetes mellitus (T2DM), despite the longer duration of disease in T1DM than in T2DM and the important differences in the underlying pathophysiology.

Furthermore, the phenotype of T1DM is changing. As a result of the findings of the Diabetes Control and Complications Trial (DCCT), which compared intensive glycemic control with usual care, and its follow-up observational study, Epidemiology of Diabetes Interventions and Complications (EDIC), intensive management of diabetes mellitus (DM) has become the standard of care and has led to increasing longevity. However, our understanding of CVD in T1DM comes in large part from the previous era of less intensive glycemic control. More intensive glycemic control is associated with significant risk of weight gain, which may be magnified by the obesity epidemic. There is growing interest in better understanding the adverse effects of glycemia, the prevalence and type of lipid abnormalities in T1DM, the prognostic role of albuminuria and renal insufficiency, and the role of blood pressure (BP) in CVD. Obesity-associated metabolic abnormalities such as the proinflammatory state likely modify CVD risk in T1DM; however, the effect may be different from what is seen in T2DM. These concepts, and how they may affect management, have not been fully explored.

The present review will focus on the importance of CVD in patients with T1DM. We will summarize recent observations of potential differences in the pathophysiology of T1DM compared with T2DM, particularly with regard to atherosclerosis. We will explore the implications of these concepts for treatment of CVD risk factors in patients with …

FRIDAY, Oct. 24, 2014 (HealthDay News) — Cardiovascular disease (CVD) is a long-term complication of type 1 diabetes mellitus (T1DM), and more attention toward management of its associated risk factors and modifiers is urged in a scientific statement published in the October issue of Diabetes Care.

Sarah D. de Ferranti, M.D., M.P.H., from the Boston Children’s Heart Foundation, and colleagues reviewed the evidence relating to CVD in T1DM, focusing on the importance of CVD, treatment of CVD risk factors, and identifying knowledge gaps.

The researchers note that CVD is a long-term complication of T1DM; CVD events are more common and occur earlier than in patients without diabetes. CVD presents at a younger age in T1DM than in T2DM, and also affects women at rates equal to those seen in men. Atherosclerosis is more diffuse and concentric in T1DM, and additional studies are needed to further understand atherosclerosis in T1DM. CVD risk factors and modifiers in T1DM include age, disease duration, as well as hyperglycemia, diabetic kidney disease, dyslipidemia, hypertension, prehypertension, and unhealthy behaviors. These risk factors should be addressed for CVD risk management. There are currently no CVD risk-prediction algorithms in widespread use for patients with T1DM. The use of novel processes and novel biomarkers on the accuracy of risk prediction is unclear in the T1DM population.

”Much work remains to be done to improve our understanding of T1DM and to help ameliorate the CVD effects of this important disease,” the authors write.

Nyhetsinfo

www red DiabetologNytt